The bi-specific CD3 x NCAM antibody: A model to preactivate T cells prior to tumour cell lysis

Clinical and Experimental Immunology

Volumn 134, Issue 2, 2003, Pages 253-263

  Jensen, M ^a   Ernestus, K ^a   Kemshead, J ^b   Klehr, M ^a   Von Bergwelt Baildon, M S ^a   Schinkothe T ^a   Schultze, J L ^a   Berthold, F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bispecific antibodies; Natural killer cells; Neural cell adhesion molecule; Neuroblastoma; T cell activation

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OE 1; NERVE CELL ADHESION MOLECULE; OKT 3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NATURAL KILLER CELL; NEUROBLASTOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEURAL CELL ADHESION MOLECULES; NEUROBLASTOMA; T-LYMPHOCYTES;

EID: 0242606042     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02300.x     Document Type: Article

References (29)

1. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59:1261-77.
2. Kushner B, Kramer K, Cheung N. Phase II trial of the anti-G (D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19:4189-94.
3. Cheung N, Kushner B, Cheung I et al. Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16:3053-60.
4. Kremens B, Hero B, Esser J et al. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 MoAb ch14.18 for neuroblastoma. Cancer Immunol Immunother 2002; 51:107-10.
5. Bourne S, Patel K, Walsh F, Popham C, Coakham H, Kemshead J. A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm. J Neurooncol 1991; 10:111-9.
6. Roy D, Ouellet S, Le HC, Ariniello P, Perreault C, Lambert J. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Natl Cancer Inst 1996; 88:1136-45.
7. Hirano T, Hirohashi S, Kunii T, Noguchi M, Shimosato Y, Hayata Y. Quantitative distribution of cluster 1 small cell lung cancer antigen in cancerous and non-cancerous tissues, cultured cells and sera. Jpn J Cancer Res 1989; 80:348-55.
8. Krushel L, Tai M, Cunningham B, Edelman G, Crossin K. Neural cell adhesion molecule (N-CAM) domains and intracellular signaling pathways involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci USA 1998; 95:2592-6.
9. Dehal P, Embleton M, Kemshead J, Hawkins R. Targeted cytokine delivery to neuroblastoma. Biochem Soc Trans 2002; 30:518-20.
10. Staerz U, Kanagawa O, Bevan M. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314:628-31.
11. Featherstone C. Bispecific antibodies: the new magic bullets. Lancet 1996; 348:536.
12. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526-34.
13. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335:368-71.
14. Jung G, Brandl M, Eisner W et al. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ T-cell activation and therapeutic efficacy. Int J Cancer 2001; 91:225-30.
15. Canevari S, Stoter G, Arienti F et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87:1463-9.
16. Hombach A, Tillmann T, Jensen M et al. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin Exp Immunol 1997; 108:352-7.
17. Weiner G, Kostelny S, Hillstrom J, Cole M, Link B, Wang S, Tso J. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol 1994; 152:2385-92.
18. Miescher S, Whiteside T, von Carrel SFV. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986; 136:1899-907.
19. Cardoso A, Schultze J, Boussiotis V et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88:41-8.
20. Agrawal S, Marquet J, Delfau-Larue M et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest 1998; 102:1715-23.
21. Manzke O, Tesch H, Diehl V, Bohlen H. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Meth 1997; 208:65-73.
22. 131J- labelled humen growth hormone of high specific radioactivity. Biochem J 1963; 89:114-23.
23. Scatchard G. The attraction of proteins for small molecules and ions. NY Acad Sci 1949; 51:660-72.
24. Hell K, Lorenzen J, Hansmann M, Fellbaum C, Busch R, Fischer R. Expression of the proliferating cell nuclear antigen in the different types of Hodgkin's disease. Am J Clin Pathol 1993; 99:598-603.
25. Bohlen H, Manzke O, Engert A, Hertel M, Hippler-Altenburg R, Diehl V, Tesch H. Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation. J Immunol Meth 1994; 173:55-62.
26. Hughes M, Marsden H, Palmer M. Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 1974; 34:1706-11.
27. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12.
28. Malygin A, Somersalo K, Timonen T. Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies. Immunology 1994; 81:92-5.
29. Sivori S, Falco M, Marcenaro E et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002; 99:4526-31.